Comparative clinical outcomes of adults with obstructive sleep apnea and comorbid obesity receiving tirzepatide versus bariatric metabolic surgery: A Multi-Institutional propensity score matched study
Main finding · Primary composite outcomeResult — go to the resultHazard ratio 0.87 95 % CI 0.66–1.15Authors' conclusion
In adults with OSA and obesity, tirzepatide demonstrated similar overall clinical outcomes to BMS. While no significant differences were observed in composite outcomes, all-cause mortality, or MACE, tirzepatide was associated with a significantly lower rate of kidney-related complications.
Study context
- Population
- Adults with obstructive sleep apnea (OSA) and comorbid obesityPropensity score matching (PSM)-matched cohort
- Participants
- 10,269 vs 10,269
- Exposure
- Tirzepatide vs bariatric metabolic surgery
- Tirzepatiden = 10,269
- Bariatric metabolic surgery (BMS)n = 10,269reference
- Outcome
- Composite of:
- All-cause mortality
- MACE
- Major adverse kidney events (MAKE)
Methodological detailspropensity score matched, multi-institutional, TriNetX Global Collaborative Network
- Propensity score matched
- Multi-institutional
- TriNetX Global Collaborative Network
Main finding
Primary composite outcome
Hazard ratio
0.87
95 % CI 0.66–1.15
P = 0.335
Tirzepatidevs BMS
HR 0.87 (95 % CI 0.66–1.15); P = 0.335
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| MAKELower rate of MAKE with tirzepatide · component of primary composite outcome | 0.60 (0.42–0.87) | P = 0.006 | |
| 0.512Hazard ratio (log scale) |
All-cause mortality
- No significant difference between groups; HR
- 0.90
- 95% CI
- 0.56-1.46
- P
- P = 0.672
- Component of primary composite outcome
Major adverse cardiovascular events (MACE)
- No significant difference between groups; HR
- 1.16
- 95% CI
- 0.85-1.56
- P
- P = 0.344
- Component of primary composite outcome
Original publication
Comparative clinical outcomes of adults with obstructive sleep apnea and comorbid obesity receiving tirzepatide versus bariatric metabolic surgery: A Multi-Institutional propensity score matched study. Diabetes Res Clin Pract. Published 31 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →